IMTX
NASDAQ · Biotechnology
Immatics Nv
$8.62
-0.20 (-2.27%)
Financial Highlights (FY 2026)
Revenue
57.72M
Net Income
-234,928,223
Gross Margin
—
Profit Margin
-407.0%
Rev Growth
-34.6%
D/E Ratio
0.03
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | — | — | 33.2% | 33.2% |
| Operating Margin | -377.1% | -339.4% | -15.4% | -12.4% |
| Profit Margin | -407.0% | -386.7% | -10.9% | -15.0% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 57.72M | 88.30M | 330.72M | 310.79M |
| Gross Profit | — | — | 109.78M | 103.16M |
| Operating Income | -217,677,172 | -299,693,215 | -50,879,176 | -38,649,824 |
| Net Income | -234,928,223 | -323,444,088 | -35,950,365 | -46,474,411 |
| Gross Margin | — | — | 33.2% | 33.2% |
| Operating Margin | -377.1% | -339.4% | -15.4% | -12.4% |
| Profit Margin | -407.0% | -386.7% | -10.9% | -15.0% |
| Rev Growth | -34.6% | -34.6% | -2.7% | -3.3% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 20.65M | 20.65M | 416.60M | 451.59M |
| Total Equity | 639.25M | 639.25M | 804.78M | 720.44M |
| D/E Ratio | 0.03 | 0.03 | 0.52 | 0.63 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | -206,703,476 | -300,395,138 | -62,958,224 | -63,441,351 |
| Free Cash Flow | — | — | -53,039,983 | -41,589,145 |